23andMe Investor Presentation Deck

Our Lead CD96 Program Was Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature Large I/O market with over $41B expected in 2021 sales 2021 projected sales of leading checkpoint inhibitors KEYTRUDA $17.0B OPDIVO YERVOY $7.9B $1.8B CD96 axis validated with ML and AI applied to our proprietary I/O genetic signature which also identifies marketed I/O drugs Source: Evaluate Pharma historical and forecast estimates. I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes tonsillectomy 11d- anti tn alpha or dmards- juvenile 11d- iqb.dry skin frequency lodine treatment ever hypothyroidism- hyperthyroidism- hashimotos- graves vitigo- iqb.dandruff frequency" celiac HLA al- psoriasis rheumatoid arthritis- look meds anti inf alpha- thyroid removed- immunodeficiency- squamous cell carcinoma- basal cell carcinoma actinic keratosis non melanoma skin cancer- any skin cancer- Autoimmune Cancer We discovered the signaling pathway has a similar genetic I/O signature CD96 plays an important role in regulating NK and T cell antitumor activity APC/Tumor cell GSK 608 T cell/NK cell CD96 Copyright © 2022 23and Me, Inc. + CD155 CD226 ITIM GSK'608 (anti-CD96) is progressing through a Phase 1 multiple-ascending dose trial in patients with advanced solid tumors 23and Me TIGIT 38

View entire presentation